Introduction {#s1}
============

Continuous positive airway pressure (CPAP) is the treatment of choice for patients with obstructive sleep apnoea (OSA), regardless of disease severity \[[@C1], [@C2]\]. CPAP has been shown to decrease elevated blood pressure, improve cardiovascular disease outcomes, and reduce the risk of fatal and nonfatal cardiovascular events \[[@C3]--[@C5]\]. It also improves excessive daytime sleepiness and restores impaired cognitive function \[[@C6]\].

Adherence to CPAP therapy is necessary for achieving satisfactory treatment outcomes \[[@C7]\]. However, CPAP compliance tends to be suboptimal, both in terms of treatment acceptance and hours of CPAP use per night, with compliance reported to be as low as 30--60% \[[@C8]\]. Although therapy acceptance depends on patient characteristics, equipment-related factors are crucial in determining CPAP adherence.

Automatic CPAP (APAP) is an alternative treatment for CPAP-intolerant OSA patients \[[@C1]\] and was developed to improve compliance. APAP devices reduce mean nocturnal pressure by automatically adjusting the delivered pressure based on the changing requirements of the patient \[[@C9]--[@C14]\]. Accordingly, APAP therapy might be more suitable for patients who have a variety of pressure demands during sleep based on factors such as body posture, sleep stage or variability between nights \[[@C15]--[@C19]\]. However, data on the advantage of APAP over CPAP for the general population of OSA patients remain controversial \[[@C20], [@C21]\]. APAP does seem to be better suited for specific OSA phenotypes, although defining the optimal target population for this therapy requires further research.

Given the technical complexity of APAP engineering, each manufacturer designs its own solution to detect disturbed breathing events and potential artefacts selectively, and to define a strategy for automatic adaptation of nasal pressure. Therefore, the use of different proprietary algorithms in APAP devices usually leads to distinct responses to the same sleep-related breathing conditions. As a result, devices from different manufacturers cannot be considered equal, particularly with respect to clinical performance. Despite existing studies comparing APAP technologies, the ongoing development of more technologically advanced devices and their availability on the market means that objective analyses are required to provide reliable data on which to base clinical decisions. Thus, the aim of this study was to compare the responses of several currently available APAP devices using a bench test simulation of OSA disturbed breathing patterns.

Methods {#s2}
=======

The bench test method used in this study was described in detail previously \[[@C22], [@C23]\]. Briefly, the bench test simulator comprised a flow generator controlled by a computer. The piston-based flow generator can reproduce mathematically designed breathing flows or replicate respiratory flows of patients recorded during polysomnography (PSG). A computer-controlled obstruction valve allows the simulation of central or obstructive events. The bench platform is equipped with two sensors (one for pressure and one for flow) and data are recorded on the computer for subsequent analysis. Conventional tubing connects the APAP device under test to the simulated OSA patient.

The disturbed breathing events employed in this study were extracted from real PSG recordings of OSA patients as previously described \[[@C22]\]. The simulator was set to reproduce the breathing events depending on the positive airway pressure (PAP) applied ([figure 1](#F1){ref-type="fig"}): 1) apnoeas with obstruction for PAP \<5 cmH~2~O; 2) severe hypopnoeas for PAP between 5 and 7 cmH~2~O; 3) mild hypopneas for PAP between 7 and 10 cmH~2~O; 4) prolonged flow limitation for PAP between 10 and 12 cmH~2~O; and 5) normal breathing for PAP \>12 cmH~2~O. Each test started with 15 min of normal breathing to simulate the time before sleep onset, followed by 2 h of simulated OSA. FIGURE 1Breathing patterns reproduced by the simulated obstructive sleep apnoea patient depending on the continuous positive airway pressure (CPAP) applied by automatic CPAP devices: a) normal breathing; b) prolonged flow limitation; c) mild hypopnoea; d) severe hypopnoea; e) apnoea with obstruction. Reproduced from \[23\] with permission from the publisher.

The study was performed on seven APAP devices currently in clinical use: AirSense 10 (A) manufactured by ResMed (San Diego, CA, USA), Dreamstar (B) by SEFAM (Villers-lès-Nancy, France), Icon (C) by Fisher & Paykel (Auckland, New Zealand), Resmart (D) by BMC (Beijing, China), Somnobalance (E) by Weinmann (Hamburg, Germany), System One (F) by Respironics (Murrysville, PA, USA) and XT-Auto (G) by Apex (New Taipei City, Taiwan). For the AirSense 10 device, two different inbuilt algorithms were tested, standard (A1) and response (A2) settings, with the Expiratory Pressure Relief setting off. Each device was equipped with its corresponding tubing. The minimum and maximum pressures were set at 4 and 20 cmH~2~O, respectively. Any other programmable settings were left at their default values. Ramp time was off for all devices and no humidification was used during any of the testing. Each test was repeated twice and the corresponding average result is reported.

Results {#s3}
=======

The responses of the assessed APAP devices are summarised in [table 1](#TB1){ref-type="table"}. There was considerable variation among devices, particularly with respect to the mean and maximum nasal pressures applied, the time to reach maximum nasal pressure, and the residual apnoea--hypopnoea index (number of residual obstructive events per hour). More than five residual obstructive events per hour were observed with devices B, D, F and G. Breathing normalisation (defined as the avoidance of any obstructive event: apnoea, hypopnoea or flow limitation) was only achieved with the A1, A2 and C devices. [Figure 2](#F2){ref-type="fig"} shows examples of the first 30 min of device response for one device that achieved breathing normalisation (A2) and another that was unable to overcome obstructive events (B). FIGURE 2Example of the first 30-min response of two automatic continuous positive airway pressure devices: one achieving breathing normalisation (AirSense 10, response setting (A2)) and another unable to eliminate obstructive events (Dreamstar (B)). The dashed black line represents the pressure required to achieve breathing normalisation (12 cmH~2~O). TABLE 1Reponses of automatic continuous positive airway pressure (APAP) devices to obstructive sleep apnoea simulated by the bench test**APAP device*P***~**max**~ **cmH~2~O*t***~**max**~ **min*P***~**mean**~ **cmH~2~OResidual AHI events per hBreathing normalisationA1**17.9, 17.822.4, 19.014.6, 14.62.0, 2.0Yes , yes**A2**15.4, 15.640.3, 57.713.4, 13.52.0, 1.5Yes, yes**B**10.5, 10.5130.6, 121.36.7, 7.974.5, 71.0No, no**C**13.4, 13.928.0, 44.112.4, 12.23.0, 3.0Yes, yes**D**10.7, 10.775.1, 103.79.7, 9.726.5, 32.5No, no**E**10.4, 10.420.7, 18.910.2, 10.23.5, 2.5No, no**F**11.9, 12.134.4, 36.010.1, 10.111.5, 13No, no**G**10.5, 11.032.2, 83.29.9, 9.933, 26.5No, no[^1]

The assessed devices also showed different performances in the rate of pressure increase after occurrence of the first obstructive event. Tracings of the initial 10 min of the test results are shown in [figure 3](#F3){ref-type="fig"}. Device A1 responded to obstructive events with a step-wise increase in pressure sufficient to overcome obstruction (mean maximum pressure 17.9 cmH~2~O). A2 increases in pressure were more gradual but the pressures reached (mean maximum 15.5 cmH~2~O) were sufficient to normalise breathing. Devices C and E also showed a rapid and pronounced pressure increase after the first obstructive event, even if only device C reached a pressure sufficient to normalise breathing (mean maximum 13.6 cmH~2~O). The other devices increased pressure more slowly and none of them was able to completely normalise breathing. FIGURE 3Pressure increase delivered by the tested automatic continuous positive airway pressure devices during the first 10 min of the bench test. The dashed black line represents the pressure required to achieve breathing normalisation (12 cmH~2~O). A1: AirSense 10, standard setting; A2: AirSense 10, response setting; B: Dreamstar; C: Icon; D: Resmart; E: Somnobalance; F: System One; G: XT-Auto.

Discussion {#s4}
==========

This bench test investigated the response of seven currently used APAP devices and found marked differences in their responses to a simulated breathing pattern mimicking that of an OSA patient. Only two devices were able to achieve breathing normalisation and to reach a residual AHI \<5, although the nasal pressures reached in some cases were higher than those required to normalise breathing in the simulated patient. Moreover, the rate of pressure increase in response to obstructive events was considerably different when comparing the tested APAP devices.

The findings obtained when testing currently available devices in this study are similar to those in previous reports, which showed variability in the response of APAP devices when subjected to the same breathing pattern under well-controlled conditions \[[@C22]--[@C24]\]. Thus, the fact that APAP devices behave differently should not be attributable to the lack of technical maturity originally found in new technologies but to the manufacturers strategy of offering devices with differentiated functioning features aimed at better treating patients. In fact, it is most likely that this inter-device response variation can be attributed to the different in-built algorithms operating in each device. The first step in the algorithms incorporated into APAP devices should analyse the pressure/flow data recorded by in-built transducers to identify different types of breathing events (*e.g.* apnoeas, hypopneas, snoring and flow limitation).The algorithm must also distinguish breathing events from artefacts (*e.g.* swallowing, coughing and speaking). Indeed, variation among devices response will depend significantly on the detection of events with no well-established definition, such as flow limitation, the detection of which remains open to interpretation. Therefore, the ability of a device to recognise and classify this event depends on the potential agreement between the specific flow limitation pattern simulated in the bench study and the event definition implemented in the APAP device algorithm.Once breathing events have been detected, the algorithm should decide when and for how long to modify the applied nasal pressure. The differences observed in this study were, therefore, not unexpected and do not necessarily imply incorrect device performance. For instance, the optimal rate of pressure increase after detection of obstructive events, which varied considerably between the devices tested ([figure 3](#F3){ref-type="fig"}), is not clear. Specifically, a difficult balance needs to be found between a response that is fast enough to ensure avoidance of disturbed breathing and soft enough to avoid patient awakening in response to a sudden nasal pressure increase.In addition, it should be noted that default settings were used during testing of most of the devices in this study and that it is possible that selecting other response thresholds could have an impact on their performance. Whether or not such modifications would increase the number of devices able to normalise breathing under the test conditions used in this study or the values of nasal pressure applied to normalise breathing is unknown.

Although bench testing is useful to understand and characterise the response of APAP devices under well-controlled conditions, this evaluation method has some limitations. Defining a model of OSA patient does not allow reproduction of the almost infinite variation in breathing events observed in clinical practice, or uncontrolled mask leaks, snoring or mouth expiration. Accordingly, it is possible that the responses of the tested devices would have been different from those reported if OSA was simulated by another model. In fact, bench testing should be considered a preliminary evaluation before the device is fully assessed in the clinical setting. However, this testing has shown that the high residual AHI seen in some devices should be further investigated in clinical practice to ensure that patients using these devices do have their sleep apnoea effectively treated. Bench test results can thus be useful when selecting the most suitable device for each patient to improve comfort and treatment compliance, and when interpreting the results of clinical studies if different devices are involved.

In conclusion, this bench study showed considerable response differences between several currently used APAP devices when subjected to a specific simulated OSA breathing pattern. Although APAP is a useful therapy, these results underline the concept that the actual implementation of APAP depends on the product-specific engineering solutions and algorithms adopted by each manufacturing company, which has implications for clinical application.

Lessons for clinicians {#s4a}
======================

-   This bench test study assessed how currently available APAP devices respond to a simulated OSA patient. Regardless of the simplified experimental setting employed in this work, as compared with the complexity of events found in the clinical arena when treating OSA patients, the following practical lessons can be derived.

-   The way that each commercial APAP device modifies nasal pressure when subjected to disturbed breathing patterns is different.

-   These differences in response among APAP devices are not necessarily caused by incorrect performances. Instead, they are the result of the particular engineering solutions implemented in each device.

-   Knowing the specific functioning features of each APAP device (*e.g.* sensitivity in detecting the different obstructive events, tolerance to events before increasing pressure and speed of pressure changes) may help to understand treatment compliance in specific patient phenotypes.

-   Choosing the optimal APAP device for the needs/preferences of each individual patient may improve therapy compliance.
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[^1]: The two values for each variable correspond to the results obtained in the two test repetitions in each device. *P*~max~: maximum positive airway pressure applied; *t*~max~: time to reach *P*~max~±0.3 cmH~2~O; *P*~mean~: mean positive airway pressure; AHI: apnoea--hypopnoea index; A1: AirSense 10, standard setting; A2: AirSense 10, response setting; B: Dreamstar; C: Icon; D: Resmart; E: Somnobalance; F: System One; G: XT-Auto.
